Drugs / TELRATOLIMOD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02556463 | Nov 2015 → Oct 2018 | primary cutaneous T-cell lymphoma | MedImmune LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TELRATOLIMOD | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297631 ↗ |
| Known as | 3M-052 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297631 ↗ |
| Known as | MEDI9197 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02556463 ↗ |
| Action | Activate | “MEDI9197 is an intratumorally administered toll-like receptor 7 and 8 agonist” PMID 33037117 ↗ Oct 2020 |
| Modality | Small molecule | — CHEMBL4297631 ↗ |
| Route | Other | “Administered intratumorally” NCT02556463 ↗ |
| Target | TLR7 | “Toll-like receptor 7 agonist” CHEMBL4297631 ↗ |
| Target | TLR8 | “Toll-like receptor 8 agonist” CHEMBL4297631 ↗ |